{"title":"Aripiprazole-Induced Gambling Disorder as an Adverse Drug Reaction in Tourette Syndrome: A Case Report.","authors":"David Kiefner, Dae-In Chang, Georg Juckel","doi":"10.1055/a-2984-7514","DOIUrl":"https://doi.org/10.1055/a-2984-7514","url":null,"abstract":"<p><strong>Abstract: </strong>Aripiprazole is recommended as a first-line treatment for Tourette syndrome but has been associated with new-onset impulse control disorders, including pathological gambling, as highlighted by a 2016 Food and Drug Administration safety warning. Gambling disorder has rarely been reported in patients with Tourette syndrome receiving aripiprazole. We report a 43-year-old man with schizoaffective disorder and comorbid childhood-onset Tourette syndrome. Gambling behaviour began after an aripiprazole dose increase, persisted for about 12 months, and was diagnosed roughly 1.5 years after aripiprazole was started. Within weeks of tapering, gambling ceased and did not recurred over a 5-year follow-up. To our knowledge, this is the first reported case of gambling disorder as a possible adverse drug reaction to aripiprazole in a patient with comorbid Tourette syndrome. We hypothesise that partial D2/D3 agonism on an already sensitised dopaminergic system could have contributed; this remains speculative. Long-term monitoring of such patients should be considered.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149334848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dingzhong Tang, Yongchuan Shi, Weibo Zhou, Ling Chen, Naichao Lin, Yuping Liang, Yan Jiang, He Chuan, Na Liu, Jian Wan, Min Zhou
{"title":"Baicalein Protects against Repeated Unpredictable Stress-Induced Depression-like Behavior in Mice.","authors":"Dingzhong Tang, Yongchuan Shi, Weibo Zhou, Ling Chen, Naichao Lin, Yuping Liang, Yan Jiang, He Chuan, Na Liu, Jian Wan, Min Zhou","doi":"10.1055/a-2975-3128","DOIUrl":"https://doi.org/10.1055/a-2975-3128","url":null,"abstract":"<p><strong>Abstract: </strong>Baicalein, an active flavonoid derived from the root of <i>Scutellaria baicalensis</i>, has been extensively utilized in the treatment of stress-related neuropsychiatric disorders, encompassing behaviors indicative of depression and anxiety. The precise neurochemical and molecular biological mechanisms underlying the effect of baicalein on depression-like behavior have yet to be elucidated. In the current study, mice were administered baicalein at dosages of 10, 20, or 40 mg/kg (intraperitoneally) 30 minutes before being subjected to daily exposure to unpredictable stress over a period of 14 days. The tail suspension test and the forced swimming test, along with the novelty suppressed feeding test and the sucrose preference test, were employed to assess the protective effects of baicalein against depression- and anxiety-like behaviors induced by chronic stress. The outcomes indicated that baicalein notably reduced the duration of immobility in both the forced swimming test and tail suspension test, elevated sucrose consumption, and diminished the latency to feed, thereby reflecting its antidepressant and anxiolytic properties. Additionally, baicalein elevated the concentrations of serotonin and dopamine and suppressed monoamine oxidase activity within the hippocampus and cortex of stressed mice. Following baicalein treatment, the levels of cyclic adenosine monophosphate and the messenger RNA expression of the brain-derived neurotrophic factor were also observed to increase in these brain regions. These results suggest that baicalein may safeguard mice from depression- and anxiety-like behaviors precipitated by chronic stress, potentially through the augmentation of monoamine levels by inhibiting monoamine oxidase activity, and by stimulating the production of cyclic adenosine monophosphate and brain-derived neurotrophic factor in brain areas implicated in emotional disorders. Baicalein could prove to be a significant agent for the prevention or mitigation of the multifaceted symptoms associated with depression and anxiety.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149323763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PharmacopsychiatryPub Date : 2026-11-01Epub Date: 2026-07-07DOI: 10.1055/a-2890-8455
Imrich Blasko, Magdalena Bühler, Lukas Gasteiger, Daniel Niederbrunner, Timo Schurr, Laurin Mauracher
{"title":"Association of seizure quality markers with postictal autonomic tone-the postictal heart rate correlates with seizure duration in electroconvulsive therapy.","authors":"Imrich Blasko, Magdalena Bühler, Lukas Gasteiger, Daniel Niederbrunner, Timo Schurr, Laurin Mauracher","doi":"10.1055/a-2890-8455","DOIUrl":"10.1055/a-2890-8455","url":null,"abstract":"<p><strong>Background and objectives: </strong>Hemodynamic changes constitute a component of the autonomic nervous system arousal in response to seizures induced by electroconvulsive therapy. Fluctuations in heart rate and blood pressure are the result of changes in the tone of the autonomic nervous system. This study investigates how changes in heart rate and blood pressure rate are related to electroconvulsive therapy quality parameters.</p><p><strong>Methods: </strong>The heart rate and blood pressure values from 29 patients across 112 sessions were retrospectively assessed and associated with electroconvulsive therapy seizure parameters. Electroconvulsive therapy seizure parameters, i.e., the stimulation charge, duration of the electroencephalography seizure, postictal suppression index, average seizure energy index, maximum sustained coherence, and mid-ictal amplitude, were used in linear mixed-effects models.</p><p><strong>Results: </strong>The duration of the seizure predicted the postictal increase in heart rate, independently on the applied stimulus charge, parameters of seizure properties or interhemispheric synchronicity and postictal central inhibition capacity. Systolic and diastolic blood pressures showed only a non‑significant trend toward an increase after the electroconvulsive therapy seizure.</p><p><strong>Conclusions: </strong>Efforts to prolong the seizure duration while optimizing electroconvulsive therapy quality parameters may be associated with an elevated heart rate and may confer an additional burden for patients with cardiac disease.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"376-381"},"PeriodicalIF":2.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13754406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PharmacopsychiatryPub Date : 2026-11-01Epub Date: 2026-04-29DOI: 10.1055/a-2858-0331
Georg Juckel, Kai Wetzel, Paraskevi Mavrogiorgou
{"title":"Clinical and Neurobiological Findings in a Patient With Unipolar Depressive 48-hour-ultrarapid-cycling.","authors":"Georg Juckel, Kai Wetzel, Paraskevi Mavrogiorgou","doi":"10.1055/a-2858-0331","DOIUrl":"10.1055/a-2858-0331","url":null,"abstract":"<p><strong>Objective: </strong>The rare cases of patients with 48-hour bipolar or unipolar ultra-rapid-cycling allow a more precise understanding of mood cycles in affective disorders, as the rhythmic changes in the psychopathological state and biological parameters are quite precise.</p><p><strong>Methods: </strong>A 73-year-old male patient with several years of recurrent affective-depressive disorder (International Classification of Diseases, 10th Revision: F33.1) developed unipolar 48-hour-ultra-rapid-cycling with 1 day of severe depression up to acute suicidality and 1 day of euthymia (International Classification of Diseases, 10th Revision: F31.8) at the beginning of 2024.</p><p><strong>Results: </strong>Ultra-rapid-cycling could be objectified both psychopathologically (Beck Depression Inventory and visual analogue scale) and neurobiologically (especially serotonin using loudness dependence of auditory evoked potentials) at the end of the year. The patient responded promptly to the subsequent adjustment to 900 mg daily lithium and has been symptom-free and with-out a 48-hour rhythm ever since.</p><p><strong>Conclusions: </strong>Unipolar depressive 48-hour-ultra-rapid-cycling of marked mood and drive fluctuations is also associated with characteristic biological changes, and that lithium represents a successful treatment strategy here in contrast to \"normal\" rapid-cycling.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"382-387"},"PeriodicalIF":2.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147778035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PharmacopsychiatryPub Date : 2026-11-01Epub Date: 2026-07-07DOI: 10.1055/a-2896-4218
Eric D Achtyes, Tasha Glenn, John R Geddes, Rita Bauer, Michael Bauer, Michael Gitlin, Scott Monteith
{"title":"Ongoing Changes in Web Searches for Health-Related Information.","authors":"Eric D Achtyes, Tasha Glenn, John R Geddes, Rita Bauer, Michael Bauer, Michael Gitlin, Scott Monteith","doi":"10.1055/a-2896-4218","DOIUrl":"10.1055/a-2896-4218","url":null,"abstract":"","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"388-390"},"PeriodicalIF":2.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Greater Depressive Symptom Severity is Associated with Increased Odds of Analgesic Use.","authors":"Shakila Meshkat, Qiaowei Lin, Aida Golshan, Vanessa K Tassone, Reinhard Janssen-Aguilar, Wendy Lou, Venkat Bhat","doi":"10.1055/a-2892-1148","DOIUrl":"10.1055/a-2892-1148","url":null,"abstract":"<p><strong>Introduction: </strong>Although pain and depression frequently co-occur, the relationship between depressive symptom severity and both the odds and duration of analgesic use remains underexplored. This study investigated the relationship between depressive symptoms and analgesic use, with particular attention to the duration of use.</p><p><strong>Methods: </strong>A cross-sectional analysis was conducted using data from the 2005-2018 National Health and Nutrition Examination Survey. Depressive symptoms were assessed using the Patient Health Questionnaire-9.</p><p><strong>Results: </strong>A total of 36,023 participants (51.14% women) were included. Each 1-point increase in the Patient Health Questionnaire-9 score was associated with a higher likelihood of analgesic use (adjusted odds ratio=1.08 and 95% confidence interval: 1.07-1.09). Compared to individuals with minimal depressive symptoms, those with mild (adjusted odds ratio=1.66 and 95% confidence interval: 1.45-1.90), moderate (adjusted odds ratio=2.17 and 95% confidence interval: 1.77-2.67), and severe symptoms (adjusted odds ratio=2.97, 95% confidence interval: 2.41-3.67) had progressively higher odds of analgesic use. Overall, depressive symptoms were associated with more than twice the odds of analgesic use (adjusted odds ratio=2.13 and 95% confidence interval: 1.82-2.48). Higher Patient Health Questionnaire-9 scores were associated with increased odds of longer analgesic use (>15 d; adjusted odds ratio=1.05 and 95% confidence interval: 1.02-1.08), as was the presence of depressive symptoms (adjusted odds ratio=1.73 and 95% confidence interval: 1.21-2.48). This association was most pronounced among individuals with severe depressive symptoms (adjusted odds ratio=2.58 and 95% confidence interval: 1.46-4.57).</p><p><strong>Discussion: </strong>Depressive symptoms were significantly associated with both increased likelihood and longer duration of analgesic use. These findings highlight the complex and potentially bidirectional relationship between pain and mental health, suggesting the need for integrated approaches to pain management and psychiatric care.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"358-366"},"PeriodicalIF":2.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Association between Intravenous Ketamine Treatment and Cognitive Function in Patients with Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Trial.","authors":"Kie Nomoto, Yohei Ohtani, Taisuke Yatomi, Kengo Yonezawa, Sota Tomiyama, Nobuhiro Nagai, Keisuke Kusudo, Shiori Honda, Sotaro Moriyama, Shinichiro Nakajima, Mie Matsui, Takashige Yamada, Hiroshi Morisaki, Kimio Yoshimura, Tsuyoshi Eiro, Sakiko Tsugawa, Sadamitsu Ichijo, Yu Fujimoto, Tomoyuki Miyazaki, Takuya Takahashi, Hiroyuki Uchida, Hideaki Tani","doi":"10.1055/a-2894-5681","DOIUrl":"10.1055/a-2894-5681","url":null,"abstract":"<p><strong>Introduction: </strong>While the rapid and robust effects of ketamine on depressive symptoms in treatment-resistant depression (TRD) have been demonstrated, the influence of ketamine treatment on cognitive function has not yet been fully elucidated. We aimed to evaluate the effects of ketamine treatment on cognitive function as part of a study that investigated the efficacy of repeated ketamine administration in patients with TRD. In addition, we conducted an exploratory analysis to examine whether baseline cognitive function was associated with ketamine response.</p><p><strong>Methods: </strong>In this double-blind, randomized, placebo-controlled study, 34 Japanese TRD patients were enrolled and assigned randomly into either ketamine or placebo group. They received ketamine 0.5 mg/kg or saline intravenously for four doses. Objective and subjective cognitive functions were evaluated with a comprehensive assessment battery before and after the intervention. We also assessed depressive symptoms with the Montgomery-Åsberg Depression Rating Scale (MADRS). The response was defined by at least a 50% reduction in the total MADRS score.</p><p><strong>Results: </strong>No significant differences were found between the ketamine and placebo groups on objective or subjective cognitive function scale score changes. Moreover, ketamine responders showed a significant improvement in subjective cognitive function compared to non-responders. The participants who demonstrated less inhibitory control at baseline showed greater MADRS score reductions after the ketamine treatment.</p><p><strong>Discussion: </strong>Repeated ketamine administration did not significantly deteriorate cognitive function compared to placebo, which supports a possible cognitive safety profile in patients with TRD. In addition, baseline impaired cognitive control may be associated with ketamine response.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"367-375"},"PeriodicalIF":2.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PharmacopsychiatryPub Date : 2026-11-01Epub Date: 2026-06-10DOI: 10.1055/a-2853-4984
Friederike Amann, Gudrun Hefner, Peter Cremer-Schaeffer, Gerhard Gründer, Winfried Häuser, Xenia M Hart, Frank Petzke, Gerald Zernig, Ursula Havemann-Reinecke
{"title":"Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.","authors":"Friederike Amann, Gudrun Hefner, Peter Cremer-Schaeffer, Gerhard Gründer, Winfried Häuser, Xenia M Hart, Frank Petzke, Gerald Zernig, Ursula Havemann-Reinecke","doi":"10.1055/a-2853-4984","DOIUrl":"10.1055/a-2853-4984","url":null,"abstract":"<p><strong>Abstract: </strong>Medical cannabis, nabiximols, dronabinol and nabilone are used for various medical conditions. Despite their pronounced pharmacokinetic variability and complex concentration-effect relationships, therapeutic drug monitoring recommendations are lacking. We aimed to identify therapeutic reference ranges based on blood concentration-clinical effect relationships. Studies reporting blood concentrations and clinical effects/adverse effects or assessing cannabinoid receptors 1 and 2 occupancy were selected through a systematic literature search in the MEDLINE database via PubMed. Twenty-three articles were selected for vaporized/smoked medical cannabis, three for nabiximols, nine for dronabinol and one for nabilone. No article was identified for delta-9-tetrahydrocannabinol-dominant cannabis extracts. For vaporized/smoked medical cannabis, an orienting therapeutic reference range of 15-30 ng/mL delta-9-tetrahydrocannabinol was identified for pain reduction in diabetic peripheral neuropathy, while concentrations of <20 ng/mL delta-9-tetrahydrocannabinol were significantly correlated with intraocular pressure reduction and 7.5-10 ng/mL with improvement of tic symptoms. Half-maximum effective concentrations of 7-29 ng/mL delta-9-tetrahydrocannabinol were reported for \"high\" effects. For nabiximols, a preliminary therapeutic reference range of 1-10 ng/mL delta-9-tetrahydrocannabinol was determined for treating neuropathic pain and spasticity in adults with multiple sclerosis. For chemotherapy-induced nausea and vomiting, a preliminary therapeutic reference range of 1-5 ng/mL for nabilone and 5-15 ng/mL delta-9-tetrahydrocannabinol for dronabinol was assessed. In conclusion, relatively low concentrations may be sufficient to achieve therapeutic effects across all substances studied, with medical cannabis demonstrating these effects at lower concentrations than typically observed in recreational use. Nevertheless, adverse effects at therapeutic reference ranges cannot be excluded.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"345-357"},"PeriodicalIF":2.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13754407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148219422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Age Differences in the Associations of Dietary and Urinary Caffeine and Its Metabolites with Depressive Symptoms.","authors":"Mahdi Mahdavi, Qiaowei Lin, Shakila Meshkat, Reinhard Janssen-Aguilar, Jithin Joseph, Wendy Lou, Venkat Bhat","doi":"10.1055/a-2967-9757","DOIUrl":"https://doi.org/10.1055/a-2967-9757","url":null,"abstract":"<p><strong>Objective: </strong>We examined associations between caffeine intake, urinary caffeine biomarkers, and depressive symptoms across age groups.</p><p><strong>Methods: </strong>We analyzed the National Health and Nutrition Examination Survey from 2005 to 2018 data from 30,817 adults aged≥18 years, categorized as younger (18-39 y), middle-aged (40-59 y), and older (≥ 60 y). Dietary caffeine, assessed using two 24-hour recalls, was modeled continuously and categorically (< 100, 100 to<200, and≥200 mg/d). Urinary caffeine and metabolites were measured in a 2009-2014 subsample (<i>n</i>=4,378). A nine-item Patient Health Questionnaire score of≥10 was considered to indicate depressive symptoms. Survey-weighted multivariable models estimated associations and caffeine-by-age interactions.</p><p><strong>Results: </strong>The adjusted dietary caffeine and age interaction was significant for a nine-item Patient Health Questionnaire score of≥10 (<i>F</i>[4,77]=2.912, <i>p</i>=0.027), but not for the total nine-item Patient Health Questionnaire score (<i>p</i>=0.522). Among older adults, high versus low intake was associated with greater odds of a nine-item Patient Health Questionnaire score of≥10 (adjusted odds ratio=1.64, 95% confidence interval: 1.23-2.20). The spline model similarly showed an age interaction (<i>F</i>[2,80]=3.782, <i>p</i>=0.027), with predicted probabilities increasing mostly among older adults. Higher log urinary caffeine was associated with greater odds of a nine-item Patient Health Questionnaire score of≥10 among older adults (adjusted odds ratio=1.24, 95% confidence interval: 1.07-1.42; false discovery rate-adjusted <i>p</i>=0.012), although the global age interaction was not significant (false discovery rate-adjusted <i>p</i>=0.470). No adjusted urinary biomarker association with the total nine-item Patient Health Questionnaire score was significant.</p><p><strong>Conclusion: </strong>Associations were outcome-specific: age modified the association between dietary caffeine and the presence of depressive symptoms, but not mean symptom severity. Among older adults, high intake was associated with greater odds of depressive symptoms.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149245840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Single-Item Anhedonia in Schizophrenia Marks Illness Severity but Does Not Independently Predict Outcomes: An Item-Level Reanalysis of the Clinical Antipsychotic Trials of Intervention Effectiveness Trial.","authors":"Alessandro Serretti","doi":"10.1055/a-2975-2221","DOIUrl":"https://doi.org/10.1055/a-2975-2221","url":null,"abstract":"<p><strong>Introduction: </strong>Anhedonia has been proposed as a marker of poor functional outcomes in schizophrenia. A model that omits baseline functioning estimates a different quantity from one that includes it: the former assesses whether anhedonia identifies patients who function worse later, and the later assesses whether it adds prognostic information beyond baseline functioning. We estimated both associations using data from the Clinical Antipsychotic Trials of Intervention Effectiveness trial.</p><p><strong>Methods: </strong>We reanalysed the Clinical Antipsychotic Trials of Intervention Effectiveness Phase 1/1A Main Trial schizophrenia sample (759 rated and decisive model 672). We moved from the first quantity to the second quantity by removing the Heinrichs-Carpenter Quality of Life Scale anhedonia item from the outcome and then adding the baseline function. We repeated the test on the three Quality of Life Scale subscales without the item, screened all 21 items the same way, set anhedonia against 15 other baseline features, and tested independent outcomes, drug interactions and attrition.</p><p><strong>Results: </strong>Baseline anhedonia predicted the 21-item Quality of Life Scale total at 12 months (standardised <i>β</i>=0.309, <i>p</i>=4.2×10<sup>-15</sup>). Removing the item from the outcome measure did not change the association (<i>β</i>=0.301). Adding the baseline function collapsed it (<i>β</i>=0.022, <i>p</i>=0.58). All 21 items behaved the same way: 21 were significant in models with no baseline term, 21 with the item also removed, and 0 once baseline function was adjusted. Anhedonia ranked 13th of 21 items, 13th of 16 features, and predicted no independent outcomes.</p><p><strong>Conclusion: </strong>Baseline single-item anhedonia in Clinical Antipsychotic Trials of Intervention Effectiveness marks concurrent clinical and functional burden. It carries no incremental prognostic value beyond the baseline function.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}